CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (62,293)	$ (27,029)	$ (41,307)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	85	151	367
Accretion related to marketable securities	(1,141)	(894)	(170)
Stock-based compensation	3,003	2,147	2,692
Gain from sale of property and equipment	(5)		(22)
Change in fair value of warrant liability	33,377
Loss from equity method investment	3,197	5,284	10,005
Changes in operating assets and liabilities:
Accounts receivable - related party	(49)	562	(81)
Prepaid and other current assets	(1,587)	(8)	581
Operating lease right-of-use assets	(28)	1,068	973
Other assets	(543)	40	107
Accounts payable	1,057	(451)	411
Accrued and other liabilities	(245)	(3,578)	467
Operating lease liability	(252)	(1,227)	(1,046)
Net cash used in operating activities	(25,424)	(23,935)	(27,023)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of marketable securities	(70,119)	(47,048)	(66,191)
Maturities of marketable securities	42,630	62,623	43,162
Purchases of property and equipment		(34)	(269)
Proceeds from sale of property and equipment	5		22
Net cash (used in) provided by investing activities	(27,484)	15,541	(23,276)
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Proceeds from issuance of common stock, net (includes $1,794 in aggregate gross proceeds from related parties)	16,405
Proceeds from issuance of pre-funded warrants, net (includes $1,769 in aggregate gross proceeds from related parties)	5,031
Proceeds from issuance of common warrants (includes $1,472 in aggregate gross proceeds from related parties)	8,934
Proceeds from the exercise of warrants	18,590
Proceeds from issuance of common stock in connection with at-the-market offering, net		7,843
Proceeds from exercise of common stock options	68	12
Net cash provided by financing activities	49,028	7,855	0
Net decrease in cash and cash equivalents	(3,880)	(539)	(50,299)
Cash and cash equivalents at beginning of the period	12,620	13,159	63,458
Cash and cash equivalents at end of the period	8,740	$ 12,620	$ 13,159
Supplemental disclosures of cash flow information
Transfer of warrant liability to additional paid-in capital upon exercise of common stock warrants	$ 13,401